BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 17710982)

  • 1. Diagnostic accuracy of MRI/MRSI for patients with persistently high PSA levels and negative TRUS-guided biopsy results.
    Bhatia C; Phongkitkarun S; Booranapitaksonti D; Kochakarn W; Chaleumsanyakorn P
    J Med Assoc Thai; 2007 Jul; 90(7):1391-9. PubMed ID: 17710982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy.
    Yuen JS; Thng CH; Tan PH; Khin LW; Phee SJ; Xiao D; Lau WK; Ng WS; Cheng CW
    J Urol; 2004 Apr; 171(4):1482-6. PubMed ID: 15017203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml.
    Kumar V; Jagannathan NR; Kumar R; Thulkar S; Gupta SD; Hemal AK; Gupta NP
    NMR Biomed; 2007 Feb; 20(1):11-20. PubMed ID: 16894640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of magnetic resonance spectroscopic imaging ([¹H]MRSI) and dynamic contrast-enhanced MRI (DCE-MRI) in identifying prostate cancer foci in patients with negative biopsy and high levels of prostate-specific antigen (PSA).
    Panebianco V; Sciarra A; Ciccariello M; Lisi D; Bernardo S; Cattarino S; Gentile V; Passariello R
    Radiol Med; 2010 Dec; 115(8):1314-29. PubMed ID: 20852963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCA3 urinary test versus 1H-MRSI and DCEMR in the detection of prostate cancer foci in patients with biochemical alterations.
    Panebianco V; Sciarra A; De Berardinis E; Busetto GM; Lisi D; Buonocore V; Gentile V; Di Silverio F; Passariello R
    Anticancer Res; 2011 Apr; 31(4):1399-405. PubMed ID: 21508392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy.
    Sciarra A; Panebianco V; Ciccariello M; Salciccia S; Cattarino S; Lisi D; Gentilucci A; Alfarone A; Bernardo S; Passariello R; Gentile V
    Clin Cancer Res; 2010 Mar; 16(6):1875-83. PubMed ID: 20197480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
    Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
    BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study.
    Amsellem-Ouazana D; Younes P; Conquy S; Peyromaure M; Flam T; Debré B; Zerbib M
    Eur Urol; 2005 May; 47(5):582-6. PubMed ID: 15826747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeat transrectal ultrasound biopsies with additional targeted cores according to results of functional prostate MRI detects high-risk prostate cancer in patients with previous negative biopsy and increased PSA - a pilot study.
    Arsov C; Quentin M; Rabenalt R; Antoch G; Albers P; Blondin D
    Anticancer Res; 2012 Mar; 32(3):1087-92. PubMed ID: 22399637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy.
    Parivar F; Hricak H; Shinohara K; Kurhanewicz J; Vigneron DB; Nelson SJ; Carroll PR
    Urology; 1996 Oct; 48(4):594-9. PubMed ID: 8886066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Localising prostate cancer: comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy.
    Goris Gbenou MC; Peltier A; Addla SK; Lemort M; Bollens R; Larsimont D; Roumeguère T; Schulman CC; van Velthoven R
    Urol Int; 2012; 88(1):12-7. PubMed ID: 22004874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparametric MRI of the prostate with three functional techniques in patients with PSA elevation before initial TRUS-guided biopsy.
    Hauth E; Hohmuth H; Cozub-Poetica C; Bernand S; Beer M; Jaeger H
    Br J Radiol; 2015 Oct; 88(1054):20150422. PubMed ID: 26268144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of MRI/MRSI-based transrectal ultrasound biopsy in peripheral and transition zones of the prostate gland in patients with prior negative biopsy.
    Testa C; Schiavina R; Lodi R; Salizzoni E; Tonon C; D'Errico A; Corti B; Morselli-Labate AM; Franceschelli A; Bertaccini A; Manferrarik F; Grigioni WF; Canini R; Martorana G; Barbiroli B
    NMR Biomed; 2010 Nov; 23(9):1017-26. PubMed ID: 20882642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours.
    Cirillo S; Petracchini M; Della Monica P; Gallo T; Tartaglia V; Vestita E; Ferrando U; Regge D
    Clin Radiol; 2008 Aug; 63(8):871-9. PubMed ID: 18625351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy?
    Salami SS; Ben-Levi E; Yaskiv O; Ryniker L; Turkbey B; Kavoussi LR; Villani R; Rastinehad AR
    BJU Int; 2015 Apr; 115(4):562-70. PubMed ID: 25252133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance imaging of the prostate with spectroscopic imaging using a surface coil. Initial clinical experience.
    Manenti G; Squillaci E; Carlani M; Mancino S; Di Roma M; Simonetti G
    Radiol Med; 2006 Feb; 111(1):22-32. PubMed ID: 16623302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging.
    Beyersdorff D; Taupitz M; Winkelmann B; Fischer T; Lenk S; Loening SA; Hamm B
    Radiology; 2002 Sep; 224(3):701-6. PubMed ID: 12202702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study.
    Kumar R; Nayyar R; Kumar V; Gupta NP; Hemal AK; Jagannathan NR; Dattagupta S; Thulkar S
    Urology; 2008 Oct; 72(4):859-63. PubMed ID: 18329078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation.
    Mowatt G; Scotland G; Boachie C; Cruickshank M; Ford JA; Fraser C; Kurban L; Lam TB; Padhani AR; Royle J; Scheenen TW; Tassie E
    Health Technol Assess; 2013 May; 17(20):vii-xix, 1-281. PubMed ID: 23697373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct comparison of targeted MRI-guided biopsy with systematic transrectal ultrasound-guided biopsy in patients with previous negative prostate biopsies.
    Kaufmann S; Kruck S; Kramer U; Gatidis S; Stenzl A; Roethke M; Scharpf M; Schilling D
    Urol Int; 2015; 94(3):319-25. PubMed ID: 25227711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.